Thailand

ViiV Healthcare's Positive Action on HIV/AIDS

Set up in 1992, Positive Action is ViiV Healthcare's international HIV/AIDS education, care and community support program. It works with community organizations to build capacity to counter the ignorance and stigma surrounding HIV and AIDS through outreach, education and advocacy. In 2009, ViiV Healthcare provided more than GBP 1 million, funding projects in 46 countries across Africa, Asia, Latin America and Eastern Europe.

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

Save the Children

Since 1998, Johnson & Johnson has partnered with Save the Children in efforts to educate children and their families in the Philippines, Thailand and Vietnam about child development, health and nutrition. The partnership's first project involved integrating personal, community and environmental hygiene instruction into school curricula in Thailand. Johnson & Johnson has provided more than USD 1.1 million in grants, contributions, matching gifts and in-kind gifts.

Sanofi-aventis: Diabetes Prevention

In 2006, sanofi-aventis launched pilot programs to help improve diabetes disease management in developing countries, in conjunction with the NGO Handicap International, Sante Diabete Mali and other local NGOs in Africa, Asia and Latin America. Several projects were set up in 2007 in Burundi, India, Kenya, Madagascar, Nicaragua, Philippines and Thailand. The program aims to help local health care systems to manage the disease better, prevent the onset of complications and so avoid the subsequent need for surgical interventions such as amputation.

Ranbaxy R&D for Malaria

Arterolane maleate, or RBx-11160, is a synthetic version of artemisinin discovered by the University of Nebraska Medical Center, Omaha, under a Medicines for Malaria Venture (MMV) program. Being synthetic, arterolane is not dependent on the artemisia annua plant-based supply chain which has presented some challenges to increasing the availability of artemisinin combination treatments (ACTs), and may also offer cost advantages. A partnership between Ranbaxy and MMV was initiated in May 2003 to develop the compound into a new anti-malarial medicine.

Pfizer Global Health Partnerships

Pfizer has a responsibility to direct its resources and expertise to address the world's most enduring health challenges. Cancer is one of these challenges and Pfizer recognizes that only by working together with those who share a vision of a healthier world can we make a significant impact toward eradicating this disease that has outlived too many generations. Pfizer's Global Health Partnerships (GHP) Program is one approach it is taking to tackle the global cancer epidemic.

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pfizer - PDA Positive Partnership

Since 2004, Pfizer Foundation New York, Pfizer Thailand Foundation and the Population and Community Development Association (PDA) have collaborated to improve the quality of life of people living with HIV/AIDS. This micro-credit loan scheme provides economic security for people living with AIDS while reducing stigmatization and discrimination in their communities. Since 2007, the Pfizer Thailand Foundation has provided financial support for the program and has worked together with PDA to equip project members with technical skills.

Pediatric Dengue Vaccine Initiative (PDVI)

Dengue fever is the second most widespread tropical disease after malaria. The Pediatric Dengue Vaccine Initiative (PDVI), a Bill and Melinda Gates funded initiative of the International Vaccine Institute, in Seoul, Korea, was established in 2001 to accelerate the development of a dengue vaccine that is appropriate, safe and accessible to poor children in endemic countries.

Novo Nordisk: Haemophilia Foundation

The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005 to address the significant need to improve haemophilia treatment in developing countries, where it is not a healthcare priority and many patients go undiagnosed or are inadequately treated. Consequently, life expectancy for people with haemophilia is low and treatment with clotting factors is suboptimal. NNHF is an independent trust, located in Zurich, Switzerland, and funds programs to improve hemophilia care, treatment and awareness in the developing world.

Pages